Drug intelligence / Profile preview

AVC-202

Development stage: Preclinical
Lead developer: AvenCell Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

AVC-202 is an investigational allogeneic chimeric antigen receptor T-cell (CAR-T) therapy being developed by AvenCell Therapeutics for the treatment of multiple myeloma. The therapy is engineered using AvenCell's proprietary TruAllo™ technology platform, which is designed to create 'off-the-shelf' cell products that can persist in the patient by overcoming graft-versus-host disease (GvHD) and rejection by the host's immune system. Unlike autologous CAR-T therapies that require patient-specific manufacturing, AVC-202 aims to provide a scalable, readily available treatment option. As of current public disclosures, the specific biological target of the CAR construct in AVC-202 remains undisclosed.

Beyond the preview

Go deeper on AVC-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVC-202.

Explore the full profile